婴儿急性淋巴细胞白血病的风险分层治疗:日本儿童白血病/淋巴瘤研究组MLL-10试验报告
该试验将90例婴儿急性淋巴细胞白血病按KMT2A状态、年龄及中枢神经系统白血病分为低危、中危、高危三组,对KMT2A重排患者引入强化化疗并仅限高危组行造血干细胞移植。KMT2A重排患者3年无事件生存率为66.2%,KMT2A胚系患者为93.3%;早期巩固末微小残留病≥0.01%与女性为不良预后因素。
要点
- KMT2A重排婴儿急性淋巴细胞白血病3年无事件生存率为66.2%,KMT2A胚系者为93.3%。
- 中危组3年无事件生存率94.4%,高危组56.6%。
- 早期巩固末微小残留病≥0.01%和女性是不良预后显著因素。
核心结论
- 本研究的风险分层和强化化疗有效,使部分KMT2A重排婴儿急性淋巴细胞白血病患者免于造血干细胞移植。
- 微小残留病早期清除似乎转化为良好结局,应纳入未来试验的风险分层。
研究设计与样本
- 日本儿童白血病/淋巴瘤研究组MLL-10试验,纳入90例符合条件的婴儿急性淋巴细胞白血病患者。
- 按KMT2A状态、年龄及中枢神经系统白血病 presence 分为低危(n=15)、中危(n=19)、高危(n=56)三组。
- 对KMT2A重排患者引入儿童肿瘤组AALL0631改良化疗(早期强化阶段加用大剂量阿糖胞苷),造血干细胞移植仅限高危患者。
- 评估微小残留病的作用。
- 试验注册于大学医院医疗信息网络临床试验注册库(UMIN-CTR),注册号#UMIN000004801。
主要发现
- KMT2A重排(中危+高危)患者3年无事件生存率为66.2%(标准误5.6%),KMT2A胚系(低危)患者为93.3%(标准误6.4%)。
- 中危组3年无事件生存率为94.4%(标准误5.4%),高危组为56.6%(标准误6.8%)。
- 多变量分析中,女性和早期巩固末微小残留病≥0.01%为不良预后显著因素。
关键数值与推荐
- 风险分层依据KMT2A状态、年龄及中枢神经系统白血病 presence。
- KMT2A重排患者接受儿童肿瘤组AALL0631改良化疗,早期强化阶段加用大剂量阿糖胞苷。
- 造血干细胞移植选项仅限高危患者。
- 早期巩固末微小残留病≥0.01%和女性为不良预后显著因素。
临床怎么用
- 本研究的风险分层和强化化疗使部分KMT2A重排婴儿急性淋巴细胞白血病患者免于造血干细胞移植。
- 微小残留病早期清除似乎转化为良好结局,作者建议将其纳入未来试验的风险分层。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The prognosis for infants with acute lymphoblastic leukemia (ALL), particularly those with KMT2A gene rearrangement (KMT2A-r), is dismal. Continuous efforts have been made in Japan to investigate the role of hematopoietic stem cell transplantation (HSCT) for infants with KMT2A-r ALL, but improvement in outcome was modest. In the Japanese Pediatric Leukemia/Lymphoma Study Group MLL-10 trial, infants with ALL were stratified into 3 risk groups (low risk [LR], intermediate risk [IR], and high risk [HR]) according to KMT2A status, age, and presence of central nervous system leukemia. Children's Oncology Group AALL0631 modified chemotherapy with the addition of high-dose cytarabine in early intensification was introduced to KMT2A-r patients, and the option of HSCT was restricted to HR patients only. The role of minimal residual disease (MRD) was also evaluated. Ninety eligible infants were stratified into LR (n = 15), IR (n = 19), or HR (n = 56) risk groups. The 3-year event-free survival (EFS) rate for patients with KMT2A-r ALL (IR + HR) was 66.2% (standard error [SE], 5.6%), and for those with germline KMT2A (KMT2A-g) ALL (LR), the 3-year EFS rate was 93.3% (SE, 6.4%). The 3-year EFS rate was 94.4% (SE, 5.4%) for IR patients and 56.6% (SE, 6.8%) for HR patients. In multivariable analysis, female sex and MRD ≥0.01% at the end of early consolidation were significant factors for poor prognosis. Risk stratification and introduction of intensive chemotherapy in this study were effective and were able to eliminate HSCT for a subset of infants with KMT2A-r ALL. Early clearance of MRD seems to have translated into favorable outcomes and should be incorporated into risk stratifications in future trials. This trial was registered at the University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR) as #UMIN000004801.
引用
- Tomizawa D, Miyamura T, Imamura T, et al. A risk-stratified therapy for infants with acute lymphoblastic leukemia: a report from the JPLSG MLL-10 trial. Blood. 2020. PMID: 32845001. doi:10.1182/blood.2019004741
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。